ALLO
Price
$1.19
Change
+$0.02 (+1.72%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
257.38M
63 days until earnings call
NTLA
Price
$11.61
Change
+$0.18 (+1.58%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.22B
70 days until earnings call
Interact to see
Advertisement

ALLO vs NTLA

Header iconALLO vs NTLA Comparison
Open Charts ALLO vs NTLABanner chart's image
Allogene Therapeutics
Price$1.19
Change+$0.02 (+1.72%)
Volume$29.88K
Capitalization257.38M
Intellia Therapeutics
Price$11.61
Change+$0.18 (+1.58%)
Volume$39.1K
Capitalization1.22B
ALLO vs NTLA Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. NTLA commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a StrongBuy and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (ALLO: $1.16 vs. NTLA: $11.42)
Brand notoriety: ALLO and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 38% vs. NTLA: 59%
Market capitalization -- ALLO: $257.38M vs. NTLA: $1.22B
ALLO [@Biotechnology] is valued at $257.38M. NTLA’s [@Biotechnology] market capitalization is $1.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 6 bearish.
  • NTLA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а +9.43% price change this week, while NTLA (@Biotechnology) price change was +11.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.10%. For the same industry, the average monthly price growth was +14.72%, and the average quarterly price growth was +30.35%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 30, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.22B) has a higher market cap than ALLO($257M). NTLA YTD gains are higher at: -2.058 vs. ALLO (-45.540). ALLO has higher annual earnings (EBITDA): -223.22M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. ALLO (273M). ALLO has less debt than NTLA: ALLO (79.2M) vs NTLA (103M). NTLA has higher revenues than ALLO: NTLA (52.9M) vs ALLO (0).
ALLONTLAALLO / NTLA
Capitalization257M1.22B21%
EBITDA-223.22M-501.87M44%
Gain YTD-45.540-2.0582,212%
P/E RatioN/AN/A-
Revenue052.9M-
Total Cash273M460M59%
Total Debt79.2M103M77%
FUNDAMENTALS RATINGS
ALLO vs NTLA: Fundamental Ratings
ALLO
NTLA
OUTLOOK RATING
1..100
661
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6563
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (26) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that NTLA’s stock grew significantly faster than ALLO’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as ALLO (97). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

NTLA's Price Growth Rating (63) in the Biotechnology industry is in the same range as ALLO (65). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLONTLA
RSI
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DHLSX30.17N/A
N/A
Diamond Hill Long-Short I
NREAX13.77N/A
N/A
Neuberger Berman Real Estate A
NPNAX49.94N/A
N/A
Neuberger Berman Large Cap Value A
HILFX35.50N/A
N/A
Hennessy Large Cap Financial Instl
JABGX12.17N/A
N/A
JHancock Real Estate Securities I